Integra LifeSciences Holdings Corporation (NASDAQ:IART – Get Free Report) shot up 6.4% on Friday . The company traded as high as $19.67 and last traded at $19.7420. Approximately 134,645 shares changed hands during mid-day trading, a decline of 85% from the average daily volume of 887,979 shares. The stock had previously closed at $18.56.
Analyst Ratings Changes
A number of brokerages recently weighed in on IART. Citigroup reissued a “neutral” rating and issued a $19.00 price target (up from $16.00) on shares of Integra LifeSciences in a report on Wednesday, July 8th. Truist Financial boosted their target price on shares of Integra LifeSciences from $14.00 to $19.00 and gave the company a “hold” rating in a research note on Thursday, July 16th. Wells Fargo & Company lifted their price objective on Integra LifeSciences from $12.00 to $15.00 and gave the stock an “equal weight” rating in a report on Wednesday, May 6th. Argus upgraded shares of Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 price target on the stock in a research note on Thursday, June 18th. Finally, Wall Street Zen downgraded Integra LifeSciences from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 18th. One equities research analyst has rated the stock with a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Reduce” and a consensus target price of $18.33.
View Our Latest Analysis on Integra LifeSciences
Integra LifeSciences Stock Up 6.6%
Integra LifeSciences (NASDAQ:IART – Get Free Report) last released its earnings results on Tuesday, May 5th. The life sciences company reported $0.54 earnings per share for the quarter, topping analysts’ consensus estimates of $0.41 by $0.13. Integra LifeSciences had a positive return on equity of 17.42% and a negative net margin of 30.15%.The company had revenue of $391.92 million during the quarter, compared to the consensus estimate of $381.81 million. During the same quarter in the previous year, the company posted $0.41 EPS. Integra LifeSciences’s quarterly revenue was up 2.4% compared to the same quarter last year. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. Analysts expect that Integra LifeSciences Holdings Corporation will post 2.45 earnings per share for the current year.
Institutional Investors Weigh In On Integra LifeSciences
Several hedge funds have recently bought and sold shares of IART. Global Retirement Partners LLC purchased a new position in Integra LifeSciences during the fourth quarter valued at $25,000. Osaic Holdings Inc. lifted its stake in shares of Integra LifeSciences by 36.6% in the second quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock worth $51,000 after buying an additional 1,104 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of Integra LifeSciences by 145.9% during the fourth quarter. GAMMA Investing LLC now owns 6,307 shares of the life sciences company’s stock valued at $78,000 after buying an additional 3,742 shares during the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of Integra LifeSciences by 595.6% during the second quarter. Tower Research Capital LLC TRC now owns 7,958 shares of the life sciences company’s stock valued at $98,000 after buying an additional 6,814 shares during the last quarter. Finally, Virtu Financial LLC bought a new stake in shares of Integra LifeSciences during the fourth quarter valued at approximately $124,000. Institutional investors own 84.78% of the company’s stock.
About Integra LifeSciences
Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.
Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.
Read More
- Five stocks we like better than Integra LifeSciences
- Telecom Earnings Reveal a Sector That Finally Looks Healthier
- Defense Earnings Show Readiness Now and Modernization Ahead
- Why Palantir Investors Aren’t Panicking While the Rest of AI Sells Off
- MarketBeat Week in Review – 07/20- 07/24
Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.
